Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis
At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19. RCTs were identified through systematic searches of PubMed, Embase, and Cochrane Central...
Saved in:
Published in | Annals of medicine (Helsinki) Vol. 55; no. 2; p. 2274511 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis Group
2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19.
RCTs were identified through systematic searches of PubMed, Embase, and Cochrane Central Register of Controlled Trials through 1 April 2023. A total of nine RCTs were included, including 30,970 COVID-19 patients comparing five treatments (azvudine, molnupiravir, paxlovid, VV116, and placebo). The Cochrane risk of bias tool for randomized trials (RoB) was used to assess the bias risk of the included studies. The direct and indirect evidence were combined using a Bayesian network meta-analysis (PROSPERO Code No: CRD42023397837).
Direct analysis showed that paxlovid was associated with a reduced risk of mortality (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.06-0.25) and hospitalization (OR = 0.04, 95% CI: 0.00-0.67) compared with placebo. Network meta-analysis showed that paxlovid had the highest probability of being the best management strategy in patients with COVID-19, reducing mortality (OR = 0.11, 95% CI: 0.01-1.99; surface under the cumulative ranking curve [SUCRA]: 0.77) and hospitalization (OR = 0.06, 95% CI: 0.00-1.03; SUCRA: 0.95). For prespecified safety outcomes, SUCRA values ranked VV116 (OR = 0.09, 95% CI: 0.00-2.07: SUCRA 0.86) as the most beneficial intervention for the prevention of serious adverse events.
When compared to other antiviral medications, paxlovid can reduce the mortality and hospitalization of COVID-19 patients. |
---|---|
AbstractList | AbstractIntroduction At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19.Methods RCTs were identified through systematic searches of PubMed, Embase, and Cochrane Central Register of Controlled Trials through 1 April 2023. A total of nine RCTs were included, including 30,970 COVID-19 patients comparing five treatments (azvudine, molnupiravir, paxlovid, VV116, and placebo). The Cochrane risk of bias tool for randomized trials (RoB) was used to assess the bias risk of the included studies. The direct and indirect evidence were combined using a Bayesian network meta-analysis (PROSPERO Code No: CRD42023397837).Results Direct analysis showed that paxlovid was associated with a reduced risk of mortality (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.06–0.25) and hospitalization (OR = 0.04, 95% CI: 0.00–0.67) compared with placebo. Network meta-analysis showed that paxlovid had the highest probability of being the best management strategy in patients with COVID-19, reducing mortality (OR = 0.11, 95% CI: 0.01–1.99; surface under the cumulative ranking curve [SUCRA]: 0.77) and hospitalization (OR = 0.06, 95% CI: 0.00–1.03; SUCRA: 0.95). For prespecified safety outcomes, SUCRA values ranked VV116 (OR = 0.09, 95% CI: 0.00–2.07: SUCRA 0.86) as the most beneficial intervention for the prevention of serious adverse events.Conclusions When compared to other antiviral medications, paxlovid can reduce the mortality and hospitalization of COVID-19 patients. INTRODUCTIONAt present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19.METHODSRCTs were identified through systematic searches of PubMed, Embase, and Cochrane Central Register of Controlled Trials through 1 April 2023. A total of nine RCTs were included, including 30,970 COVID-19 patients comparing five treatments (azvudine, molnupiravir, paxlovid, VV116, and placebo). The Cochrane risk of bias tool for randomized trials (RoB) was used to assess the bias risk of the included studies. The direct and indirect evidence were combined using a Bayesian network meta-analysis (PROSPERO Code No: CRD42023397837).RESULTSDirect analysis showed that paxlovid was associated with a reduced risk of mortality (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.06-0.25) and hospitalization (OR = 0.04, 95% CI: 0.00-0.67) compared with placebo. Network meta-analysis showed that paxlovid had the highest probability of being the best management strategy in patients with COVID-19, reducing mortality (OR = 0.11, 95% CI: 0.01-1.99; surface under the cumulative ranking curve [SUCRA]: 0.77) and hospitalization (OR = 0.06, 95% CI: 0.00-1.03; SUCRA: 0.95). For prespecified safety outcomes, SUCRA values ranked VV116 (OR = 0.09, 95% CI: 0.00-2.07: SUCRA 0.86) as the most beneficial intervention for the prevention of serious adverse events.CONCLUSIONSWhen compared to other antiviral medications, paxlovid can reduce the mortality and hospitalization of COVID-19 patients. At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19. RCTs were identified through systematic searches of PubMed, Embase, and Cochrane Central Register of Controlled Trials through 1 April 2023. A total of nine RCTs were included, including 30,970 COVID-19 patients comparing five treatments (azvudine, molnupiravir, paxlovid, VV116, and placebo). The Cochrane risk of bias tool for randomized trials (RoB) was used to assess the bias risk of the included studies. The direct and indirect evidence were combined using a Bayesian network meta-analysis (PROSPERO Code No: CRD42023397837). Direct analysis showed that paxlovid was associated with a reduced risk of mortality (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.06-0.25) and hospitalization (OR = 0.04, 95% CI: 0.00-0.67) compared with placebo. Network meta-analysis showed that paxlovid had the highest probability of being the best management strategy in patients with COVID-19, reducing mortality (OR = 0.11, 95% CI: 0.01-1.99; surface under the cumulative ranking curve [SUCRA]: 0.77) and hospitalization (OR = 0.06, 95% CI: 0.00-1.03; SUCRA: 0.95). For prespecified safety outcomes, SUCRA values ranked VV116 (OR = 0.09, 95% CI: 0.00-2.07: SUCRA 0.86) as the most beneficial intervention for the prevention of serious adverse events. When compared to other antiviral medications, paxlovid can reduce the mortality and hospitalization of COVID-19 patients. |
Author | Tian, Fangyuan Chen, Zhaoyan |
Author_xml | – sequence: 1 givenname: Zhaoyan orcidid: 0000-0002-0181-1564 surname: Chen fullname: Chen, Zhaoyan organization: Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China – sequence: 2 givenname: Fangyuan orcidid: 0000-0002-5187-0386 surname: Tian fullname: Tian, Fangyuan organization: Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37967171$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kU9v1DAQxS1URLeFjwDykUsW_4njmBtaCl2pUi_A1Zp1JiXFiRfbabUHvjtOd9vTSE9v3hvN74KcTWFCQt5ztuasZZ-YbpVsDVsLJuRaCF0rzl-RFZeNqgRr2BlZLZ5qMZ2Ti5TuGWNCc_aGnEttGs01X5F_Vw_gZ8hDmGjoaYjgaRrBezoGj272SLs43yXah0jzb6Q5IuQRp7zYN7e_tl8rbui-JBQtfaZA0yFlHIvgaMSHAR8pTB2dMD-G-IeOmKGCCfwhDekted2DT_juNC_Jz29XPzbX1c3t9-3my03laiFyJRwYA41ADtg67IRrjWp57XqtlOGKMdc1hvXYK4mm7XYARjawk0Jy7JpGXpLtMbcLcG_3cRghHmyAwT4JId5ZiOVgj7bB3gHXRgvT1uWrRjDYiUbKrlQ7BSXr4zFrH8PfGVO245Aceg8ThjlZUf6tVatFXazqaHUxpBSxf6nmzC4U7TNFu1C0J4pl78OpYt6N2L1sPWOT_wFT9poa |
CitedBy_id | crossref_primary_10_3390_jcm13071837 crossref_primary_10_1016_j_ijid_2024_107016 |
Cites_doi | 10.1126/science.abq1841 10.1001/jamanetworkopen.2023.26910 10.1136/bmj.d5928 10.1056/NEJMoa2208822 10.1038/s41579-021-00630-8 10.1016/S1473-3099(22)00320-6 10.1016/S2213-2600(22)00126-6 10.1016/S0140-6736(22)01586-0 10.1016/S0140-6736(21)02657-X 10.1186/s41231-021-00102-4 10.3390/vaccines9101064 10.1126/scitranslmed.abl7430 10.1056/EVIDoa2100043 10.1016/S2213-2600(22)00127-8 10.1056/NEJMoa2116044 10.1001/jamanetworkopen.2020.10364 10.1016/j.ijantimicag.2022.106545 10.1002/advs.202001435 10.3389/fpubh.2022.844333 10.3390/v13081585 10.1016/j.ijid.2022.10.021 10.1002/jmv.27940 10.1001/jama.2022.18931 10.1136/postgradmedj-2020-138234 10.1056/NEJMoa2118542 10.1038/d41573-020-00016-0 10.1007/s43440-022-00388-7 10.1016/S1473-3099(22)00644-2 10.3389/fphar.2022.939573 10.1038/d41573-021-v00202-8 10.1016/j.jclinepi.2010.03.016 10.1002/jmv.28732 10.1016/S0140-6736(22)02597-1 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.1080/07853890.2023.2274511 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2060 |
EndPage | 2274511 |
ExternalDocumentID | oai_doaj_org_article_6efca17972984274920ab2633de8cc5a 10_1080_07853890_2023_2274511 37967171 |
Genre | Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- .55 .GJ 00X 03L 0YH 23M 34G 36B 39C 3O- 4.4 53G 5GY 5RE 5VS AALIY AALUX AAORF AAPXX ABLKL ABUPF ABWCV ABZEW ACENM ACGEJ ACGFS ADCVX ADFZZ ADRBQ ADXPE AENEX AEOZL AFFNX AFKVX AFLEI AGYJP AIJEM AJVHN AJWEG ALMA_UNASSIGNED_HOLDINGS AWYRJ BABNJ BLEHA BOHLJ BRMBE CAG CCCUG CGR COF CS3 CUY CVF CYYVM CZDIS DKSSO DRXRE DWTOO EBD EBS ECM EIF EJD EMB EMOBN F5P GROUPED_DOAJ H13 HZ~ JENTW KRBQP KSSTO KWAYT KYCEM LJTGL M44 M4Z NPM NUSFT O9- OK1 OVD P2P QQXMO RPM SV3 TDBHL TEORI TFDNU TFL TFW V1S WH7 X7M ZGI ZXP ~1N AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c422t-2ca99a62e1ae8ced2c895814cf75591500cd690fef53e98dbaa936ab3231ed663 |
IEDL.DBID | DOA |
ISSN | 0785-3890 |
IngestDate | Fri Oct 04 13:12:16 EDT 2024 Fri Aug 16 06:30:36 EDT 2024 Fri Aug 23 02:08:17 EDT 2024 Sun Oct 13 09:28:55 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | COVID-19 meta-analysis SARS-CoV-2 small molecule randomized controlled trials |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c422t-2ca99a62e1ae8ced2c895814cf75591500cd690fef53e98dbaa936ab3231ed663 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-5187-0386 0000-0002-0181-1564 |
OpenAccessLink | https://doaj.org/article/6efca17972984274920ab2633de8cc5a |
PMID | 37967171 |
PQID | 2890758724 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6efca17972984274920ab2633de8cc5a proquest_miscellaneous_2890758724 crossref_primary_10_1080_07853890_2023_2274511 pubmed_primary_37967171 |
PublicationCentury | 2000 |
PublicationDate | 2023-00-00 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – year: 2023 text: 2023-00-00 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Annals of medicine (Helsinki) |
PublicationTitleAlternate | Ann Med |
PublicationYear | 2023 |
Publisher | Taylor & Francis Group |
Publisher_xml | – name: Taylor & Francis Group |
References | e_1_3_4_4_1 e_1_3_4_3_1 e_1_3_4_2_1 e_1_3_4_9_1 e_1_3_4_8_1 e_1_3_4_7_1 e_1_3_4_20_1 e_1_3_4_6_1 e_1_3_4_5_1 e_1_3_4_23_1 e_1_3_4_24_1 e_1_3_4_21_1 e_1_3_4_22_1 e_1_3_4_27_1 e_1_3_4_28_1 e_1_3_4_25_1 e_1_3_4_26_1 e_1_3_4_29_1 e_1_3_4_31_1 e_1_3_4_30_1 e_1_3_4_12_1 e_1_3_4_35_1 e_1_3_4_13_1 e_1_3_4_34_1 e_1_3_4_10_1 e_1_3_4_33_1 e_1_3_4_11_1 e_1_3_4_32_1 e_1_3_4_16_1 e_1_3_4_17_1 e_1_3_4_38_1 e_1_3_4_14_1 e_1_3_4_37_1 e_1_3_4_15_1 e_1_3_4_36_1 e_1_3_4_18_1 e_1_3_4_19_1 |
References_xml | – ident: e_1_3_4_31_1 doi: 10.1126/science.abq1841 – ident: e_1_3_4_29_1 doi: 10.1001/jamanetworkopen.2023.26910 – ident: e_1_3_4_14_1 doi: 10.1136/bmj.d5928 – ident: e_1_3_4_25_1 doi: 10.1056/NEJMoa2208822 – ident: e_1_3_4_13_1 doi: 10.1038/s41579-021-00630-8 – ident: e_1_3_4_27_1 doi: 10.1016/S1473-3099(22)00320-6 – ident: e_1_3_4_7_1 doi: 10.1016/S2213-2600(22)00126-6 – ident: e_1_3_4_10_1 doi: 10.1016/S0140-6736(22)01586-0 – ident: e_1_3_4_37_1 doi: 10.1016/S0140-6736(21)02657-X – ident: e_1_3_4_38_1 – ident: e_1_3_4_6_1 doi: 10.1186/s41231-021-00102-4 – ident: e_1_3_4_28_1 doi: 10.3390/vaccines9101064 – ident: e_1_3_4_19_1 doi: 10.1126/scitranslmed.abl7430 – ident: e_1_3_4_32_1 – ident: e_1_3_4_20_1 doi: 10.1056/EVIDoa2100043 – ident: e_1_3_4_5_1 doi: 10.1016/S2213-2600(22)00127-8 – ident: e_1_3_4_21_1 doi: 10.1056/NEJMoa2116044 – ident: e_1_3_4_15_1 doi: 10.1001/jamanetworkopen.2020.10364 – ident: e_1_3_4_9_1 doi: 10.1016/j.ijantimicag.2022.106545 – ident: e_1_3_4_18_1 doi: 10.1002/advs.202001435 – ident: e_1_3_4_30_1 doi: 10.3389/fpubh.2022.844333 – ident: e_1_3_4_12_1 doi: 10.3390/v13081585 – ident: e_1_3_4_16_1 doi: 10.1016/j.ijid.2022.10.021 – ident: e_1_3_4_3_1 doi: 10.1002/jmv.27940 – ident: e_1_3_4_34_1 – ident: e_1_3_4_8_1 doi: 10.1001/jama.2022.18931 – ident: e_1_3_4_2_1 doi: 10.1136/postgradmedj-2020-138234 – ident: e_1_3_4_4_1 – ident: e_1_3_4_26_1 doi: 10.1056/NEJMoa2118542 – ident: e_1_3_4_11_1 doi: 10.1038/d41573-020-00016-0 – ident: e_1_3_4_36_1 doi: 10.1007/s43440-022-00388-7 – ident: e_1_3_4_22_1 doi: 10.1016/S1473-3099(22)00644-2 – ident: e_1_3_4_24_1 doi: 10.3389/fphar.2022.939573 – ident: e_1_3_4_35_1 doi: 10.1038/d41573-021-v00202-8 – ident: e_1_3_4_17_1 doi: 10.1016/j.jclinepi.2010.03.016 – ident: e_1_3_4_33_1 doi: 10.1002/jmv.28732 – ident: e_1_3_4_23_1 doi: 10.1016/S0140-6736(22)02597-1 |
SSID | ssj0002710 |
Score | 2.4488 |
SecondaryResourceType | review_article |
Snippet | At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety... INTRODUCTIONAt present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy... AbstractIntroduction At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the... |
SourceID | doaj proquest crossref pubmed |
SourceType | Open Website Aggregation Database Index Database |
StartPage | 2274511 |
SubjectTerms | COVID-19 Humans meta-analysis Network Meta-Analysis randomized controlled trials SARS-CoV-2 small molecule |
Title | Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37967171 https://search.proquest.com/docview/2890758724 https://doaj.org/article/6efca17972984274920ab2633de8cc5a |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqHlAviEeBLVANElcviRMncW_QhwpSy4Wi3qKxPebSzVbd3WP_e8exs8AB9cJ1ZCXOzDjzje35RoiPihg2-KaQqrStrANaibUKUiNRpxXawsYN_YvL5vyq_natr_9o9RXvhCV64KS4Tw0Fh-w1DAK7mlMoowq0qqkqT51zOkGjUk_JVP4Hq3bkIeD4pyWH5GKq3Yms2iyLonlsHD5X_Ehdln9FpZG8_9-Ic4w8Z8_E0wwZ4XOa6nOxQ8ML8eQiH4q_FPenW8ZuWAaIJfewWuDNDSxS71sCf7f5tQLGp8B4D7aXy-Pw4-8_v57I0kBmWF0dAcJvfmdItS2Ag4chXRmHBa1RYmYz2RdXZ6c_js9l7qogXa3UWiqHxmDDRkLWIHnlOqO7snah5eyC8WHhPKfMgYKuyHTeIpqqQVsxEiTPAOWV2B2WA70R4DWZwrbEGsQ6BMdLOITQKEuRyNB1MzGftNrfJvKMvpw4SbMZ-miGPpthJr5E3W8HR-7rUcAe0WeP6B_ziJn4MFmu57USD0BwoOVm1cdDVc6PWlXPxOtk0u2rqtY0nNqWB_9jCm_FXvystFXzTuyu7zb0nsHL2h6Ofno47io9AAtM6aI |
link.rule.ids | 315,786,790,870,2115,4043,27954,27955,27956 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+oral+small+molecule+drugs+for+the+treatment+of+COVID-19+patients%3A+a+systematic+review+and+network+meta-analysis&rft.jtitle=Annals+of+medicine+%28Helsinki%29&rft.au=Chen%2C+Zhaoyan&rft.au=Tian%2C+Fangyuan&rft.date=2023&rft.eissn=1365-2060&rft.volume=55&rft.issue=2&rft.spage=2274511&rft_id=info:doi/10.1080%2F07853890.2023.2274511&rft_id=info%3Apmid%2F37967171&rft.externalDocID=37967171 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0785-3890&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0785-3890&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0785-3890&client=summon |